Longevity.Technology’s Post

We are excited to announce Human Longevity, Inc. as a Tier 3 Sponsor of the 11th Aging Research & Drug Discovery Meeting. Built by the pioneers of the human genome sequencing effort since 2013, Human Longevity is the global leader in advancing the Human Longevity Care movement, on a mission to discover and harness the technological and biological interventions that amplify span of life, health, & high-performance. Human Longevity, Inc. is committed to accelerating living to 100+ by revolutionizing the landscape of the current system of "sickcare" to true "healthcare". By continually adding and analyzing our client's health data, they are transforming treatment from a reactive practice to one that is proactive, preventative, and personalized. #ARDD2024 will feature a dynamic mix of academic institutions, clinicians, industry leaders, and pharmaceutical companies, fostering rich dialogues and unveiling new research in the field of aging. Mark your calendars for August 26-30, 2024 and register now at agingpharma.org https://lnkd.in/gMFJRTqZ #ARDD2024 #DrugDiscovery #AgingResearch

Advancements in technology are revolutionizing the way we combat diseases. Cutting-edge gene-editing techniques and personalized cell therapies are harnessing the power of our own cells to tackle health challenges in ways we never thought possible. With technology propelling us towards groundbreaking therapies, the possibilities are limitless. What do you believe the future of medicine will look like? #healthtech #personalizedmedicine #celltherapy

Interested in learning about trends, conversation, and innovations occurring in the viral vector-based therapy sector? Read what this panel of experts, including George Buchman, had to say at the ASGCT in the Medicine Maker Q&A article highlighting Catalent's CGT and viral vector expertise. #viralvector #genetherapy #advancedtherapies

Agree, this is a problem even with screening programs for many diseases. But we are starting to see the possibility of ‘precision’ screening, as we better identify high risk groups, based on multi factorial risk scores. The same approaches will facilitate ‘precision’ prevention trials with pharmaceuticals, and that may include predictors of frailty and fragile ageing.

💚🧬The first Gene-editing treatment is here 🧬💚 We're witnessing a monumental leap in medical science with the recent approval of the first gene-editing treatment using CRISPR technology for sickle-cell disease. This groundbreaking development not only offers hope to millions but also marks a significant advancement in biotechnology. 🧬🎉 Additionally, the emergence of new weight-loss drugs presents potent tools against obesity, with promising implications for reducing cardiovascular risks. These innovations are set to transform patient care and improve quality of life. 🚀💊🩺 👩🔬🧑🔬 Swipe to see an artistic depiction of a futuristic medical laboratory where these life-changing solutions are being developed. #HealthcareInnovation #Biotechnology #CRISPR #MedicalScience #GeneEditing #WeightLoss #CardiovascularHealth 💪💚

🔔 Only a few weeks left to get early bird discount. This is the place to be, to learn about #Cell and #genetherapy and how existing technology can be applied to solve for a rare genetic disease. If you have an interest or asset in #CysticFibrosis, #bronchiectasis, #PCD, Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF) or other rare respiratory diseases, then join us on 1st October at The Francis Crick Institute. 💊 This event is for #biotech, #pharma and #investors with an interest in #rare and #orphandrugs across the continuum of development from #pipeline to #market launch. Network with leaders in #genomics, #translational medicine, #peadiatric respiratory research.

Excited to share my first review article titled ‘Polymer-drug conjugates as nano-sized multi-targeting systems for the treatment of Alzheimer’s disease’, in the new journal, RSC Pharmaceutics. Please read and share. Dr Colin Thompson, Gemma Barron, Paul Kong Thoo Lin #alzheimersresearch #drugdelivery #rscpharmaceutics

Great article to get to know more about what we are doing at ChristianaCare to contribute to the expansion and growth of Precision Medicine.

In Part 6 (Therapeutic Area Advances) of Scrip’s annual series on biopharma’s outlook, Cuong Do, President & CEO of BioVie, predicts that we’ll see meaningful progress in #longevity and #aging research.   Read the article to learn more about what the industry’s top leaders predict for the year ahead. $BIVI #BrainHealth #AlzheimersDisease #ParkinsonsDisease

Thankful to the Scrip team for the opportunity to share my predictions for the year ahead. Abnormally increased DNA methylation (or DNA hypermethylation) is associated with age-related diseases, such as Alzheimer’s and Parkinson’s, and #inflammation is known to be implicated in this process.   I look forward to seeing data from investigational therapies, including our lead candidate NE3107, that progress the use of DNA methylation as a biomarker of #aging and what might be possible by effectively reducing it.   #Dementia #Inflammation #InsulinResistance